Colesevelam

Colesevelam
Clinical data
Trade names	Welchol, Cholestagel
AHFS/Drugs.com	Monograph
MedlinePlus	a699050
License data	US DailyMed: Colesevelam;
Routes of; administration	By mouth
ATC code	C10AC04 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	N/A
Metabolism	Colesevelam is not absorbed and not metabolized
Elimination half-life	N/A (non-systemic drug)
Excretion	By intestines only, colesevelam is non-systemic
Identifiers
	IUPAC name Allylamine polymer with 1-chloro-2,3-epoxypropane, [6-(allylamino)-hexyl]trimethylammonium chloride and N-allyldecylamine, hydrochloride;
CAS Number	182815-43-6 ;
PubChem CID	160051;
DrugBank	DB00930 ;
ChemSpider	none;
UNII	1XU104G55N;
KEGG	D07743 ; as HCl: D03582 ;
ChEMBL	ChEMBL1201677 ;
Chemical and physical data
Formula	C31H67Cl3N4O
Molar mass	618.25 g·mol−1
	(what is this?) (verify)

Colesevelam is a bile acid sequestrant administered orally. It was developed by GelTex Pharmaceuticals and later acquired by Genzyme. It is marketed in the US by Daiichi Sankyo under the brand name Welchol and elsewhere by Genzyme as Cholestagel. In Canada, it is marketed by Valeant as Lodalis.